Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
Belite Bio announced that Swissmedic has granted orphan drug status to tinlarebant for the treatment of Stargardt disease. This designation follows the successful Phase 3 DRAGON trial, which showed a 35.7% reduction in retinal lesion growth rate compared to placebo.
Key figures
- Drug Name
- tinlarebant
- Trial enrollment
- 104
- Trial jurisdictions
- 11
- Lesion growth reduction
- 35.7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.